Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Companysort icon Description Status Initial Date
<a href="/venture-capital/all-companies/medidametrics-inc">MedidaMETRICS, Inc.</a> Developing activity-based costing systems for healthcare providers. Private 2010 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Provider of leading technology for the conversion of biomass to fuels and chemicals. Private 2006 View Profile
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Advancing a technology platform for Liquid Fuel from the Sun™. Private 2007 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Discovering and developing protein therapeutics to treat diseases of the eye. Public 2008 View Profile
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Unlocking the promise of genome editing to deliver life-changing medicines. Private 2013 View Profile
<a href="/venture-capital/all-companies/ecosense-lighting%C2%AE">EcoSense Lighting®</a> Provides best-in-class solid-state lighting solutions for use in commercial and residential applications. Private 2013 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Public 2006 View Profile
<a href="/venture-capital/all-companies/celexion-llc">Celexion LLC</a> Developing powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. Private 2009 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/black-duck-software-inc">Black Duck Software, Inc.</a> Offering award-winning software and consulting. Private 2004 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Nanomedicine platform company developing Accurins, its novel targeted therapeutics. Public 2007 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Developing and delivering diagnostic solutions to aid in the clinical management of heart failure and related disorders. Public 2000 View Profile
<a href="/venture-capital/all-companies/avedro-inc">Avedro, Inc.</a> Advancing the science and technology of corneal crosslinking. Private 2009 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/affinnova-inc">Affinnova, Inc.</a> Global marketing technology company that dramatically improves innovation and marketing success rates. Private 2000 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. Public 2004 View Profile